Literature DB >> 14693694

Ceramide content is increased in skeletal muscle from obese insulin-resistant humans.

John M Adams1, Thongchai Pratipanawatr, Rachele Berria, Elaine Wang, Ralph A DeFronzo, M Cameron Sullards, Lawrence J Mandarino.   

Abstract

Increased intramyocellular lipid concentrations are thought to play a role in insulin resistance, but the precise nature of the lipid species that produce insulin resistance in human muscle are unknown. Ceramides, either generated via activation of sphingomyelinase or produced by de novo synthesis, induce insulin resistance in cultured cells by inhibitory effects on insulin signaling. The present study was undertaken to determine whether ceramides or other sphingolipids are increased in muscle from obese insulin-resistant subjects and to assess whether ceramide plays a role in the insulin resistance of Akt in human muscle. Lean insulin-sensitive and obese insulin-resistant subjects (n = 10 each) received euglycemic-hyperinsulinemic clamps with muscle biopsies basally and after 30, 45, or 60 min of insulin infusion. The rate of glucose infusion required to maintain euglycemia (reflecting glucose uptake) was reduced by >50%, as expected, in the obese subjects at each time point (P < 0.01). Under basal conditions, total muscle ceramide content was increased nearly twofold in the obese subjects (46 +/- 9 vs. 25 +/- 2 pmol/2 mg muscle, P < 0.05). All species of ceramides were increased similarly in the obese subjects; in contrast, no other sphingolipid was increased. Stimulation of Akt phosphorylation by insulin in the obese subjects was significantly reduced after 30 min (0.96 +/- 0.11 vs. 1.84 +/- 0.38 arbitrary units) or 45-60 min (0.68 +/- 0.17 vs. 1.52 +/- 0.26) of insulin infusion (P < 0.05 for both). Muscle ceramide content was significantly correlated with the plasma free fatty acid concentration (r = 0.51, P < 0.05). We conclude that obesity is associated with increased intramyocellular ceramide content. This twofold increase in ceramide may be involved in the decrease in Akt phosphorylation observed after insulin infusion and could theoretically play a role in the reduced ability of insulin to stimulate glucose uptake in skeletal muscle from obese subjects.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14693694     DOI: 10.2337/diabetes.53.1.25

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  253 in total

Review 1.  Adipokines as novel biomarkers and regulators of the metabolic syndrome.

Authors:  Yingfeng Deng; Philipp E Scherer
Journal:  Ann N Y Acad Sci       Date:  2010-11       Impact factor: 5.691

Review 2.  Role of intramyocelluar lipids in human health.

Authors:  Paul M Coen; Bret H Goodpaster
Journal:  Trends Endocrinol Metab       Date:  2012-06-20       Impact factor: 12.015

Review 3.  The role of muscle insulin resistance in the pathogenesis of atherogenic dyslipidemia and nonalcoholic fatty liver disease associated with the metabolic syndrome.

Authors:  François R Jornayvaz; Varman T Samuel; Gerald I Shulman
Journal:  Annu Rev Nutr       Date:  2010-08-21       Impact factor: 11.848

4.  Endoplasmic reticulum stress does not mediate palmitate-induced insulin resistance in mouse and human muscle cells.

Authors:  R Hage Hassan; I Hainault; J-T Vilquin; C Samama; F Lasnier; P Ferré; F Foufelle; E Hajduch
Journal:  Diabetologia       Date:  2011-10-18       Impact factor: 10.122

5.  Ceramides and glucosylceramides are independent antagonists of insulin signaling.

Authors:  Jose A Chavez; M Mobin Siddique; Siew Tein Wang; Jianhong Ching; James A Shayman; Scott A Summers
Journal:  J Biol Chem       Date:  2013-11-08       Impact factor: 5.157

6.  Training alters the distribution of perilipin proteins in muscle following acute free fatty acid exposure.

Authors:  S O Shepherd; J A Strauss; Q Wang; J J Dube; B Goodpaster; D G Mashek; L S Chow
Journal:  J Physiol       Date:  2017-06-27       Impact factor: 5.182

7.  Human skeletal muscle ceramide content is not a major factor in muscle insulin sensitivity.

Authors:  M Skovbro; M Baranowski; C Skov-Jensen; A Flint; F Dela; J Gorski; J W Helge
Journal:  Diabetologia       Date:  2008-05-06       Impact factor: 10.122

Review 8.  Sphingolipids, insulin resistance, and metabolic disease: new insights from in vivo manipulation of sphingolipid metabolism.

Authors:  William L Holland; Scott A Summers
Journal:  Endocr Rev       Date:  2008-05-01       Impact factor: 19.871

Review 9.  Insulin resistance and neurodegeneration: roles of obesity, type 2 diabetes mellitus and non-alcoholic steatohepatitis.

Authors:  Suzanne M de la Monte; Lisa Longato; Ming Tong; Jack R Wands
Journal:  Curr Opin Investig Drugs       Date:  2009-10

10.  Dual modulation of both lipid oxidation and synthesis by peroxisome proliferator-activated receptor-gamma coactivator-1alpha and -1beta in cultured myotubes.

Authors:  Daniel O Espinoza; Laszlo G Boros; Sarah Crunkhorn; Hiral Gami; Mary-Elizabeth Patti
Journal:  FASEB J       Date:  2009-11-11       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.